Groups Object After CMS Sticks With Registry Plan For Alzheimer’s Drug Coverage

The Alzheimer’s Association is calling participation in registries an “unnecessary barrier” for access to anti-amyloid drugs for Alzheimer’s disease after CMS announced it will immediately cover anti-amyloid drugs for early stages of Alzheimer’s if they receive full, traditional approval from FDA, but is holding firm that all patients receiving the drugs participate in a registry detailing the treatment’s effectiveness. In a statement released Thursday (June 1) , CMS Administrator Chiquita Brooks-LaSure says the class of drugs that aim to slow...